Brief: Cogent Biosciences Says FDA Accepts NDA With Priority Review For Bezuclastinib In Combination With Sunitinib
28/05/2026 13:17
BRIEF-Cogent Biosciences Says FDA Accepts NDA With Priority Review For Bezuclastinib In Combination With Sunitinib May 28 (Reuters) - Cogent Biosciences Inc COGT.O:
ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW FOR BEZUCLASTINIB IN COMBINATION WITH SUNITINIB FOR PATIENTS WITH GIST
FDA GRANTS PRIORITY REVIEW TO NDA WITH PDUFA DATE NOVEMBER 30, 2026
FDA DOES NOT PLAN ADVISORY COMMITTEE OR IDENTIFY REVIEW ISSUES FOR NDA
Source text: ID:nGNXbWtVNw
Further company coverage: COGT.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's